Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus XALATAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus XALATAN.
LATANOPROSTENE BUNOD vs XALATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2α analog. It is hydrolyzed by esterases in the eye to latanoprost acid and nitric oxide. Latanoprost acid increases uveoscleral outflow of aqueous humor via FP receptor agonism, while NO enhances trabecular meshwork outflow via soluble guanylate cyclase activation.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop (approximately 1.5 mcg) in the affected eye(s) once daily in the evening.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine."
Clinical Note
moderateThe terminal elimination half-life of latanoprostene bunod is approximately 17 minutes for the active metabolite (latanoprost acid) after topical ocular administration. This short half-life reflects rapid systemic clearance, consistent with once-daily dosing for intraocular pressure reduction.
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
The primary route of elimination is via the kidneys, with approximately 88% of the dose excreted in urine as metabolites; fecal excretion accounts for about 6%, and the remainder is excreted via other routes. Renal excretion of unchanged drug is minimal.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
Balsalazide + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Balsalazide."